“Safety net hospitals” serve troubled communities like Chester in Delaware County, Pennsylvania. Finance companies serve themselves.
Merrill Goozner
Merrill Goozner, a former editor of Modern Healthcare, publishes GoozNews on Substack, where this post originally appeared.
Posted inThe Monopolized Economy
How to Stop the Drug Companies from Hiking Prices for Covid Vaccines
The drug companies got rich during the pandemic through massive government subsidies. Now, they want to raise the price of lifesaving treatment. Fostering competition could keep costs down.
Posted inBooks
Medicine at the Mercy of Wall Street
The pharmaceutical industry is the great white whale of American medicine. No matter how many harpoons activists, progressive politicians, journalists, and scholars hurl at its bloated body, it not only survives, it grows fatter by feasting on the patients and payers that are the krill of the U.S. health care system. The drug price controls […]
Posted inMagazine
The Electricity Is Too Damn High
High prices at corporate-owned EV charging stations could cripple the spread of climate-friendly transportation. We need to help the mom-and-pops compete.
Posted inHealth Care
Amazon’s Health Care Ambitions
The colossus plans to acquire One Medical and put itself at the center of high-end health care.
Posted inHealth Care
GOP Hands Big Pharma a Get-Out-of-Jail-Free Card
The Inflation Reduction Act is being hailed for getting tough on drug companies. In fact, they’ll make out just fine.
Posted inMagazine
The AMA’s Dark Secret
Journalists aren’t allowed inside the supposedly public meetings where the American Medical Association
effectively decides (and ratchets up) health care prices.
Posted inHealth Care
Is a Misguided Hospital Building Boom Coming?
A $2 billion expansion of Mass General Brigham in Boston could open the floodgates.
Posted inNovember/December 2021
The Doctor Will Not See You Now
Primary care is a disaster. Consolidation is making it worse. And a revolution is coming.
Posted inFeatured, Health Care, Political Animal
That Wildly Expensive New Alzheimer’s Drug Needs Serious Testing
Why Biogen’s medication, aducanumab, should get studied through an important part of the Affordable Care Act, the Patient Centers Outcomes Research Institute.
